2019
Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation
Renaghan AD, Jaimes EA, Malyszko J, Perazella MA, Sprangers B, Rosner MH. Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. Clinical Journal Of The American Society Of Nephrology 2019, 15: 289-297. PMID: 31836598, PMCID: PMC7015091, DOI: 10.2215/cjn.08580719.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationStem cell transplantationCell transplantationKidney injuryHepatic sinusoidal obstruction syndromeAcute kidney injurySinusoidal obstruction syndromeCongenital immune deficiencyDevelopment of CKDType of transplantNonmalignant hematologic disordersStem cell transplantLife-saving therapySickle cell diseaseHigh mortality rateAcute dialysisNephrotoxic medicationsNonrelapse mortalityConditioning regimenHost diseaseInfusion syndromeObstruction syndromeThrombotic microangiopathyTransplant recipientsPatient characteristics
2018
Cancer drugs and the glomerulus
Shah H, Uppal N, Perazella M. Cancer drugs and the glomerulus. Journal Of Onco-Nephrology 2018, 2: 78-91. DOI: 10.1177/2399369318815418.Peer-Reviewed Original ResearchGlomerular lesionsCancer drugsAnti-vascular endothelial growth factor inhibitorsPoor renal outcomeAcute interstitial nephritisAcute kidney injuryAcute tubular necrosisGrowth factor inhibitorsMinimal change diseaseFocal segmental glomerulosclerosisTyrosine kinase inhibitorsNovel cancer drugsRenal outcomesKidney injuryThrombotic microangiopathyNovel immunotherapiesTubular injuryTubular necrosisInterstitial nephritisGlomerular toxicityChange diseaseFactor inhibitorsSegmental glomerulosclerosisGlomerular diseasePodocyte injury
2015
Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal Of Kidney Diseases 2015, 66: 857-868. PMID: 25943718, DOI: 10.1053/j.ajkd.2015.02.340.Peer-Reviewed Original ResearchConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsLong-term kidney injuryManagement of TMACell damageGrowth factor agentsAnti-VEGF agentsEndothelial cell damageType I agentsChemotherapy regimensDrug interruptionFactor agentsKidney injuryImmunologic basisClinical courseFunctional recoveryImmunosuppressive agentsKidney functionCertain malignanciesI agentsPhysician guidanceAnticancer therapySuccessful diagnosis